1 Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–12.
2 Diabetes UK. Diabetes: the basics. Diabetes UK, 2017. https://www.diabetes.org.uk/Diabetes-the-basics/ (accessed April 20, 2019).
3 Public Health England. Adult obesity and Diabetes.co.uk, accepting the diagnosis. https://www.diabetes.co.uk/emotions/coping-withdiabetes-diagnosis.html (accessed April 20, 2019).
4 Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37: 347–56.
5 Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603–08.
6 Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335–48.
7 Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025–31.
8 Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755–65.
9 Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781–89. 10 Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care 2013; 36: 1047–55.
11 Lingvay I, Guth E, Islam A, Livingston E. Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery? Diabetes Care 2013; 36: 2741–47.
12 Steven S, Hollingsworth KG, Small PK, et al. Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in type 2 diabetes. Diabet Med 2016; 33: 1723–31.
13 NHS England. NHS England announce type 2 remission pilot, and plans to double the size of the NHS England Diabetes Prevention Programme. Dec 14, 2018. https://www.england.nhs.uk/2018/11/verylow- calorie-diets-part-of-nhs-action-to-tackle-growing-obesity-and-type-2-diabetes-epidemic/ (accessed April 20, 2019).
14 Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669–701.
15 Steven S, Lim E, Taylor R. Population response to information on reversibility of type 2 diabetes. Diabet Med 2013; 30: e135–38.
16 Taylor R, Barnes AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. Diabet Med 2019; 36: 308–15.
17 Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007; 104: 12587–94.
18 UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–58.
19 Rudenski AS, Hadden DR, Atkinson AB, et al. Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med 1988; 5: 36–41.
20 Butler AE, Cao-Minh L, Galasso R, et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 2010; 53: 2167–76.
21 Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10 (suppl 4): 32–42.
22 Sattar N, McConnachie A, Ford I, et al. Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007; 56: 984–91.
23 Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–28.
24 Ryysy L, Hakkinen A-M, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749–58.
25 Taylor R, Magnussen I, Rothman DL, et al. Direct assessment of liver glycogen storage by 13C-nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996; 97: 126–32.
26 Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506–14.
27 Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab 2018; 28: 547–56.e3.
28 Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R. Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 2002; 283: E275–83.
29 Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287–93.
30 Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986; 35: 990–98.
31 Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496–506.
32 Ravikumar B, Gerrard J, Dalla Man C, et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008; 57: 2288–95.
33 Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339–50.
34 Perry RJ, Peng L, Cline GW, et al. Mechanisms by which a very-low-calorie diet reverses hyperglycemia in a rat model of type 2 diabetes. Cell Metab 2018; 27: 210–17.e3.
35 Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267–77.
36 Luukkonen PK, Zhou Y, Sadevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1167–75.
37 Apostolopoulou M, Gordillo R, Koliaki C, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care 2018; 41: 1235–43.
38 Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte–β-cell
relationships. Proc Natl Acad Sci USA 1994; 91: 10878–82.
39 McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7–18.
40 Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995; 44: 863–70.
41 Pinnick K, Neville M, Clark A, Fielding B. Reversibility of metabolic and morphological changes associated with chronic exposure of pancreatic islet β-cells to fatty acids. J Cell Biochem 2010; 109: 683–92.
42 Pinnick KE, Collins SC, Londos C, Gauguier D, Clark A, Fielding BA. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity (Silver Spring) 2008; 16: 522–30.
43 Huang CJ, Lin CY, Haataja L, et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated β-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007; 56: 2016–27.
44 Laybutt DR, Preston AM, Akerfeldt MC, et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007; 50: 752–63.
45 Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801: 289–98.
46 Al-Mrabeh A, Hollingsworth KG, Steven S, Taylor R. Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity. Diabetologia 2016; 59: 1753–59.
47 Al-Mrabeh A, Hollingsworth KG, Steven S, Tiniakos D, Taylor R. Quantification of intrapancreatic fat in type 2 diabetes. PLoS One 2017; 12: e0174660.
48 van der Zijl NJ, Goossens GH, Moors CC, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011; 96: 459–67.
49 Kuhn JP, Berthold F, Mayerle J, et al. Pancreatic steatosis demonstrated at MR imaging in the general population: clinical relevance. Radiology 2015; 276: 129–36.
50 Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very low calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016; 39: 158–65.
51 Steven S, Hollingsworth KG, Small P, et al. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care 2016; 39: 158–65.
52 Tushuizen ME, Bunck MC, Pouwels PJ, et al. Pancreatic fat content and β-cell function in men with and without type 2 diabetes. Diabetes Care 2007; 30: 2916–21.
53 Szczepaniak LS, Victor RG, Mathur R, et al. Pancreatic steatosis and its relationship to β-cell dysfunction in humans: racial and ethnic variations. Diabetes Care 2012; 35: 2377–83.
54 Redmon JB, Bertoni AG, Connelly S, et al. Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010; 33: 1153–58.
55 Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219–34.
56 Sevastianova K, Santos A, Kotronen A, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012; 96: 427–34.
57 Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119–21.
58 Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014; 510: 84–91.
59 Lim S, Bae JH, Chun EJ, et al. Differences in pancreatic volume, fat content, and fat density measured by multidetector-row computed tomography according to the duration of diabetes. Acta Diabetol 2014; 51: 739–48.
60 Lalloyer F, Vandewalle B, Percevault F, et al. Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006; 55: 1605–13.
61 Finlayson G, Bryant E, Blundell JE, King NA. Acute compensatory eating following exercise is associated with implicit hedonic wanting for food. Physiol Behav 2009; 97: 62–67.
62 Hopkins M, Blundell JE, King NA. Individual variability in compensatory eating following acute exercise in overweight and obese women. Br J Sports Med 2014; 48: 1472–76.
63 King NA, Horner K, Hills AP, et al. Exercise, appetite and weight management: understanding the compensatory responses in eating behaviour and how they contribute to variability in exercise-induced weight loss. Br J Sports Med 2012; 46: 315–22.
64 Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005; 82 (suppl 1): 222S–25S.
65 McCombie L, Leslie W, Taylor R, Kennon B, Sattar N, Lean MEJ. Beating type 2 diabetes into remission. BMJ 2017; 358: j4030.
66 Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT) an open-label, cluster-randomised trial. Lncet 2017; 391: 541–51.
67 Lean ME, Leslie W, Barnes AC, et al. Durability of a primary careled weight management intervention for remission of type 2
diabetes: 2-year results of the DiRECT open-label, clusterrandomised
trial. Lancet Diabetes Endocrinol 2019; 7: 344–55.
68 Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308: 2489–96.
69 Taylor R, Holman R. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond) 2015; 128: 405–10.
70 Lotta LA, Gulati P, Day FR, et al. Integrative genomic análisis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 2017;49: 17–26.
71 Peters C, Steven S, Taylor R. Reversal of type 2 diabetes by weight loss despite presence of macro- and micro-vascular complications. In: Draznin B, ed. Diabetes case studies: real problems, practical solutions. Alexandria: American Diabetes Association, 2015: 271–74.
72 Doughty R. Type 2 diabetes and the diet that cured me. The Guardian, May 12, 2013. https://www.theguardian.com/lifeandstyle/2013/may/12/type-2-diabetes-diet-cure (accessed April 20, 2019).
73 Brereton MF, Iberl M, Shimomura K, et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nat Commun 2014; 5: 4639.
74 Spijker HS, Song H, Ellenbroek JH, et al. Loss of β-cell identity occurs in type 2 diabetes and is associated with islet amyloid deposits. Diabetes 2015; 64: 2928–38.
75 Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 2012; 150: 1223–34.
76 Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab 2014; 19: 872–82.
77 White MG, Marshall HL, Rigby R, et al. Expression of mesenchymal and α-cell phenotypic markers in islet β-cells in recently diagnosed diabetes. Diabetes Care 2013; 36: 3818–20.
78 Cinti F, Bouchi R, Kim-Muller JY, et al. Evidence of β-cell dedifferentiation in human type 2 diabetes. J Clin Endocrinol Metab 2016; 101: 1044–54.
79 Sun J, Ni Q, Xie J, et al. B-Cell dedifferentiation in patients with T2D with adequate glucose control and nondiabetic chronic pancreatitis. J Clin Endocrinol Metab 2019; 104: 83–94.
80 White MG, Shaw JAM, Taylor R. Type 2 diabetes: the pathologic basis of reversible β-cell dysfunction. Diabetes Care 2016; 39: 2080–88. 81 QRISK. The QRISK2–2017 risk calculator. QRISK, 2017. https://qrisk.org/2017/ (accessed April 20, 2019).
82 Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311: 2297–304.
83 Pearce IA, Ilango B, Sells RA, Wong D. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Ophthalmol 2000; 84: 736–40.
84 Arun CS, Pandit R, Taylor R. Long-term progression of retinopathy after initiation of insulin therapy in type 2 diabetes: an observational study. Diabetologia 2004; 47: 1380–84.
85 Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment: follow-up of the Kroc Collaborative Study. JAMA 1988; 260: 37–41.
86 Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994; 97: 354–62.
87 Gregg EW, Cheng YJ, Narayan KM, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. Prev Med 2007; 45: 348–52.
88 Public Health England. Adult obesity and type 2 diabetes. July 2014. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/338934/Adult_obesity_and_type_2_diabetes_.pdf (accessed April 20, 2019).
89 Steven S, Carey PE, Small PK, Taylor R. Reversal of type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes. Diabet Med 2015; 32: 47–53.
90 Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care 2013; 36: 20–26.
91 Steinarsson AO, Rawshani A, Gudbjornsdottir S, Franzen S, Svensson AM, Sattar N. Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100 606 individuals from the Swedish National Diabetes Register. Diabetologia 2018; 61: 599–606.
92 Misra A, Sattar N, Tandon N, et al. Clinical management of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol 2018; 6: 979–991.
93 Association of Clinical British Diabetologists and Primary Care Diabetes Society Position Statement. Remission of type 2 diabetes. https://abcd.care/sites/abcd.care/files/resources/ABCD-and-PCDSfinal-statement-3 March2019.pdf (accessed April 20, 2019).
Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí